Update (9:38 a.m.): Updated with Wednesday market open information.
The stock was up 2.91% to $74.30 at 9:37 a.m. on Wednesday.
The drug would be the first such treatment in Europe.
One of the hottest biotech stocks of the last month is selling off.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
A glimpse of what to expect during Tuesday's pre-market.